BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company w...

March 30, 2026 | News

Clarity Pharmaceuticals Signs Copper 64 Supply Agreement With Theragenics To Advance Radiopharmaceutical Commercialisation

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation pr...

March 27, 2026 | News

Celosia Therapeutics Initiates Phase 1b Trial Of CTx1000 Targeting TDP 43 In ALS

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS Celosia Therapeutics, an Australian biotech company developing advanced gen...

March 25, 2026 | News

Monash University And ClinChoice Partner To Accelerate Early Phase Clinical Trials

Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, announced a strate...

March 23, 2026 | News

Australia Grants CTA For First In Human KMCAR T Cell Therapy Targeting Multiple Myeloma

Clinical Trial Approval (CTA) granted by Australia’s Therapeutic Goods Administration (TGA) for KMCAR™ T-cell, a first-in-human CAR-T cell th...

March 18, 2026 | News

BioCina Advances RLS 2201 With CMC Programme To Enable Clinical Entry

BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation (CDMO) announced it has initiated a comprehensive CMC (Chemistry,...

March 18, 2026 | News

Australian Researchers Launch Clinical Trial Exploring Hyperbaric Oxygen Therapy For High Grade Glioma

Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating ...

March 17, 2026 | News

Telix Resubmits US NDA For Pixclara PET Imaging Agent Targeting Glioma Diagnosis

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food ...

March 17, 2026 | News

Optellum Secures TGA Approval In Australia For AI Powered Virtual Nodule Clinic

Optellum, the leading AI-enabled solution for earlier lung cancer detection, is thrilled to announce that it has received Therapeutic Goods Administration ...

March 02, 2026 | News

Formosa Pharmaceuticals Signs Exclusive Licensing Agreement With Arrotex For APP13007 In Australia And New Zealand

Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...

February 24, 2026 | News

NEXT Life Sciences Advances Two Non Hormonal Male Contraceptives Into Phase II Trials

Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest...

February 23, 2026 | News

Telix Submits European Marketing Application For TLX101 Px To Expand Glioma PET Imaging Access

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has submitted a marketing authorization application (MAA) in Europe ...

February 19, 2026 | News

Delonix Bioworks Secures China IND Clearance For MenB Vaccine Candidate DX 104

Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B...

February 09, 2026 | News

Imagion Biosystems Files FDA IND For MagSense Molecular MRI Cancer Imaging Platform

Imagion Biosystems, Ltd. (ASX: IBX) announced that the company has lodged an Investigational New Drug (IND) application with the U.S. Food and Drug Adminis...

February 06, 2026 | News

Stay Connected